Bill > A03775

This bill establishes a comprehensive legal framework for the medical use of psilocybin in New York State, creating a robust regulatory system that includes several key components. The legislation defines psilocybin as a naturally occurring psychedelic compound produced by certain fungi and establishes guidelines for its medical use, including a certification process for facilitators who can administer the treatment. The bill creates a psilocybin-assisted therapy grant program specifically designed to provide funding for veterans, first responders, retired first responders, and low-income individuals to access psilocybin therapy. It also establishes a 13-member advisory board to provide recommendations on medical psilocybin use, with members appointed by the governor, senate president, and assembly speaker. The bill includes protections for patients and practitioners, ensuring they cannot be criminally prosecuted or professionally penalized for participating in certified medical psilocybin treatment. Additionally, the legislation mandates a naturally grown medical psilocybin pilot program overseen by the Department of Agriculture and Markets, with the goal of developing safe production standards and potentially seeking federal research exemptions. The bill appropriates $5 million to fund the psilocybin and MDMA assisted therapy grant program and requires the health department to conduct evaluations and report on the program's implementation and effectiveness every two years.

Health and Social Services

https://www.nysenate.gov/legislation/bills/2025/A3775